RetinalGenix Technologies Inc.

RetinalGenix Technologies Inc. is an ophthalmic research and development company focused on developing technologies to screen, provide information, and treat eye health disorders, including ophthalmic, optical, and sight-threatening conditions. The company's mission is to improve patients' lives by providing critical information to treat eye diseases and other general health conditions. Its products and services are built on four pillars: genetic testing, retinal imaging, a patient information base, and pharmaceutical therapies. The company's first products to be launched are genetic tests, planned for late 2026, starting with GPS oral swab tests. A second genetic test is being developed to identify positive responders to treatment for wet Age-related Macular Degeneration (AMD), targeted for launch in 2027. The Retinal Imaging Platform, designed for capturing quality economic pictures of the eyes, is expected to be in Beta tests in 2026 and potentially approved for commercialization in 2027. The Patient Informational Database is being designed to securely combine patient genetic and imaging data anonymously. RetinalGenix is also developing repurposed pharmaceutical products: RTG-2023 for the treatment of dry AMD and RTG-2024 for the treatment of Alzheimer's syndrome dementia. These are expected to continue development subject to adequate funding. The company is designing two devices to prevent vision loss and blindness due to ocular diseases, including diabetic retinopathy and maculopathy. One is a portable Retinal Imaging Screening Device, which is a retinal imaging system providing a wide field of view without requiring pupil dilation.